Patient description: The patient is a 31-year-old woman complaining of abdominal pain. The pain started last night as diffuse abdominal discomfort. She had poor appetite as well as malaise. The pain worsened in intensity and became sharp in the morning. The pain became localized to the right lower quadrant in the morning. The temperature is within the normal limits with normal vital signs. Focal tenderness and guarding were observed during palpation of the right lower quadrant. Palpation of the left lower quadrant causes pain on the right. Her lab work is remarkable for leukocytosis. Computed Tomography of the abdomen with contrast shows the presence of a distended appendix with thickened appendiceal wall without perforation, abscess or gangrene. She is a candidate for laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sarcoma of the Extremity Stage I Soft Tissue Sarcoma of the Trunk and Extremities Stage IA Soft Tissue Sarcoma of the Trunk and Extremities Stage IB Soft Tissue Sarcoma of the Trunk and Extremities Stage II Soft Tissue Sarcoma of the Trunk and Extremities Subjects must have a histologically confirmed diagnosis of sarcomas of the extremities (which may gluteal muscle involvement) for which neoadjuvant radiation therapy followed by surgical resection is a planned intervention Subjects whose bowel cannot be completely protected from radiation exposure due to primary tumor location (e.g., proximal lower extremity) will be excluded Subjects must have one or more measurable target lesions by version (v) 1.1, assessed via computed tomography (CT) scan or magnetic resonance imaging (MRI) At the time of study enrollment, subjects must have a tumor burden that is judged to be surgically resectable Absolute neutrophil count (ANC) >= 1500/mm^3 (>= 1.5 GI/L) without granulocyte colony-stimulating factor support in the last 28 days White blood cell count >= 2500/mm^3 (>= 2.5 GI/L) Platelets >= 100,000/mm^3 (>=100 GI/L) without transfusion in the last 28 days Hemoglobin >= 9 g/dL (>= 90 g/L) without transfusion in the last 28 days Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 3 X upper limit of normal (ULN) Alkaline phosphatase (ALP) =< 3 X upper limit of normal (ULN)  Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) for the investigational diagnosis Receipt of any prior radiation therapy for the investigational diagnosis Known central nervous system (CNS) metastases Concomitant anticoagulation with oral anticoagulants(e.g., warfarin, direct thrombin and factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following Low-dose aspirin for cardioprotection (per local applicable guidelines) is permitted Low-dose low molecular weight heparins (LMWH) are permitted Anticoagulation with therapeutic doses of LMWH is allowed in subjects without known brain metastases who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor. Subjects with hemoptysis, central nervous system hemorrhage or gastrointestinal hemorrhage within the last 6 months prior to treatment are excluded The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions Cardiovascular disorders Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias